Table 1.

Expression of EHZF in hematopoietic and nonhematopoietic cell lines


Cell type

Cell line

EHZF
Hematopoietic   
    Mega/erythroid   K-562   ++++  
  HEL   ++++  
    Megakaryoblastic   MO7e   -  
    T lymphoid   HPB-ALL   ++  
  Jurkat   ++  
  Molt-4   ++  
  H9   -  
    B lymphoid   Raji (pre-B)   ++  
  IM-9   -  
  U266   -  
  Daudi (EBV+)   -  
    Myeloid (immature)   KG-1   -  
    Myelo-monocytic   HL-60   -  
    Monocytic   THP-1   ++  
  U-937   -  
    Natural killer   Nischi   -  
Nonhematopoietic   
    Adenocarcinoma, cervix   HeLa   -  
    Adenocarcinoma, colon   CaCo2   -  
    Kidney carcinoma   293   +++  
    Bladder carcinoma   5637   -  
Hepatocarcinoma   Hep3B   -  
Embryonal
 
P19
 
++
 

Cell type

Cell line

EHZF
Hematopoietic   
    Mega/erythroid   K-562   ++++  
  HEL   ++++  
    Megakaryoblastic   MO7e   -  
    T lymphoid   HPB-ALL   ++  
  Jurkat   ++  
  Molt-4   ++  
  H9   -  
    B lymphoid   Raji (pre-B)   ++  
  IM-9   -  
  U266   -  
  Daudi (EBV+)   -  
    Myeloid (immature)   KG-1   -  
    Myelo-monocytic   HL-60   -  
    Monocytic   THP-1   ++  
  U-937   -  
    Natural killer   Nischi   -  
Nonhematopoietic   
    Adenocarcinoma, cervix   HeLa   -  
    Adenocarcinoma, colon   CaCo2   -  
    Kidney carcinoma   293   +++  
    Bladder carcinoma   5637   -  
Hepatocarcinoma   Hep3B   -  
Embryonal
 
P19
 
++
 

Amounts of EHZF mRNA were assessed by Northern blotting and by RT-PCR with specific primers using cDNA derived from 100 ng RNA. The quantity of product is indicated, when undetectable after 40 cycles of PCR as (-); when low (+), moderate (++), high (+++), or abundant (++++).

or Create an Account

Close Modal
Close Modal